The FreeStyle Libre 3 system is indicated for use in people with diabetes age 4 and older.
FreeStyle Libre 3 Plus sensor is indicated for use in people with diabetes age 2 and older.
Medicare and other payor criteria may apply. Abbott provides this information as a courtesy and does not guarantee payment or coverage.
* 60-minute warm-up required when starting the sensor.
† Among patient-applied sensors.
‡ Study was performed with the US version of the FreeStyle Libre 14 day system. Data is applicable to FreeStyle Libre 3 system, as feature sets are similar as FreeStyle Libre 14 day system, excluding alarms.
§ Retrospective observational study with average baseline A1C 10.1% ± 1.7%.
‖ This real-world study analyzed EHR claims and evaluated changes in A1C with the addition of FreeStyle Libre systems among people with Type 2 diabetes on prior GLP-1 therapy.
¶ Based on prescription claims for commercially insured patients starting on the FreeStyle Libre personal CGM systems compared to competitor CGMs. Does not include Medicare, Medicaid, uninsured, and other federal or state healthcare program patients. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.
# Based on prescription claims for the aggregate of patients covered by Commercial insurance, Managed Medicare, Managed Medicaid using the FreeStyle Libre personal CGM systems versus competitors’ CGM systems. Does not include fee-for-service Medicare, fee-for-service Medicaid, and uninsured patients. The actual amount a patient pays may vary. The FreeStyle Libre systems require a prescription.
** No prior authorization needed at participating pharmacies. This applies to commercially insured patients. This does not apply to beneficiaries of Medicare, Medicaid or other federal or state healthcare programs. Participating pharmacies are subject to change without notice.
†† The FreeStyle Libre systems apps are only compatible with certain mobile devices and operating systems. Please check the Support section of our website for more information about device compatibility before using the apps. Use of the FreeStyle Libre systems apps may require registration with LibreView.
‡‡ The FreeStyle Libre 3 app and the FreeStyle Libre 3 reader have similar but not identical features. Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol and when your glucose alarms and readings from the system do not match symptoms or expectations.
§§ Not made with this skin allergen. IBOA not detected at test method limit of detection of 0.0016 μg per device. MBPA not detected at test method limit of detection of 0.0079 μg per device.
References: 1. FreeStyle Libre 3 User’s Manual. 2. Data on file. Abbott Diabetes Care, Inc. 3. Wright, Eugene E., et al. "Use of Flash Continuous Glucose Monitoring Is Associated With A1C Reduction in People With Type 2 Diabetes Treated With Basal Insulin or Noninsulin Therapy." Diabetes Spectrum 34, no. 2 (2021): 184–189. https://doi.org/10.2337/ds20-0069. 4. Miller, Eden, et al. "Association of Changes in A1C Following Continuous Glucose Monitoring Acquisition in People with Sub-Optimally Treated Type 2 Diabetes Taking GLP-1 RA Therapy." Diabetes Therapy 15, no. 4 (2024): 2027–2038. https://doi.org/10.1007/s13300-024-01619-1. 5. Seibold, Alexander. "Minimizing Adverse Skin Reactions to Wearable Continuous Glucose Monitoring Sensors in Patients With Diabetes." Journal of Diabetes Science and Technology 15, no. 3 (2021): 713–714. https://doi.org/10.1177/1932296820984763.
ADC-55139 v11.0
Get easy patient identification tips.
